Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304740 | 0.81 | PTGS2 (0.50) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL1530698 | 0.76 | HSD17B10 (0.47) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL19100560 | 0.75 | POLB (0.32) | — | |
| SCHEMBL7968046 | 0.74 | PTGS2 (0.41) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL14112766 | 0.74 | ALOX15 (0.44) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL2618817 | 0.73 | HTT (0.49) | PTGS2ALDH1A1TSHRTDP1LMNA | |
| SCHEMBL18415081 | 0.73 | CA2 (0.39) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL12678876 | 0.73 | PTGS2 (0.40) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL1730807 | 0.73 | PTGS2 (0.40) | PTGS2ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL5737333 | 0.72 | PTGS2 (0.42) | PTGS2ALDH1A1TSHRTDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383824-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2501679-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011061243-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123489-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HCCS, EIF2AK2, RNASE1 | PTGS2 1793/4885ALDH1A1 125/4885TSHR 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.